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Abstract
Indu Mithra Madhuranthakam
BEHAVIORAL ANALYSIS OF CONDITIONS AND TREATMENTS AFFECTING
MOVEMENT AND NOCICEPTION
2019-2021
Thomas M Keck, Ph.D.
Master of Sciences in Pharmaceutical Sciences

This thesis work includes three projects. First part deals with the investigation of novel D2
receptor ligands in Prepulse inhibition. The goal of this study is to establish a relationship
between dopamine receptor antagonists and agonists and prepulse inhibition which can
then serve as a working model for an in-vivo efficacy of novel dopamine D2 drugs. The
second part of the thesis work deals with Niemann pick disease type C. Niemann pick
disease type C is a progressive genetic disorder that is characterized by the lysosomal
accumulation of lipids which causes neurodegeneration, dementia, ataxia, and death.
NPC1nmf164 mutant mice (knockout) have a delayed acquisition of motor skills during
development. The aim of our study was to identify cellular and molecular pathways
involved in causing and progressing NPC in young patients from which effective
therapeutic interventions can be designed and tested to prevent or delay the onset of the
disease and prolong and improve the quality of life of young NPC patients.Finally, the last
part of this thesis work includes studies on synergistic anithyperalgesic and antinociceptive
effects of morphine and MP-III-024, a positive allosteric modulator at α2 GABAA and
α3GABAA receptors. The purpose of this study was to examine the interactive effects of
the μ-opioid agonist morphine and the α2GABAA and α3GABAA receptor positive
allosteric modulator MP-III-024 in preclinical models of mechanical hyperalgesia and
thermal nociception.
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Chapter 1
Investigating Novel Dopamine D2 Receptor Ligands in Prepulse Inhibition
Introduction
Prepulse inhibition is the reduction in startle amplitude to an acoustic startle stimulus
when preceded by a weaker pre-stimulus within a certain time frame (fig.1). The
information processing begins during the initial 100ms following the onset of a stimuli
with a set of preattentional automatic processes in organisms with complex nervous
systems that trigger different response mechanisms, one among which is the startle
response, a neuronal reflex mechanism that prepares an organism to face a potentially
relevant stimulus. Therefore, acoustic startle response is a protective mechanism that is
elicited by a sudden and intense acoustic stimulus1. PPI is normal in healthy individuals
but impaired in patients with schizophrenia and Alzheimer’s disease due to abnormalities
in sensorimotor gating. Commercially available drugs used in the treatment of psychotic
disorders, such as the dopamine D2 receptor antagonist haloperidol, increase PPI. The
goal of this study is to establish a relationship between dopamine receptor antagonists
and agonists and prepulse inhibition which can then serve as a working model for an invivo efficacy of novel dopamine D2 drugs.
Reflex and Its Importance
Reflex is an involuntary movement that arises in response to a peripheral stimulus
and gets conducted to the nerve center in the brain or spinal cord. Spinal cord is an abode
of the centers that govern reflex movements in addition to the ones that control certain
1

groups of muscles. The reflex begins in an impulse upon the stimulation of a sensory or
afferent nerve. It is conducted to the center in the spinal cord, from the sensory cell bodies
to the neurons of the corresponding motor center. As a result, a motor impulse originates
in the motor nerve which then is transmitted to the muscle fibers that are supplied by the
nerve. This complete path is called as a reflex arc. A reflex arc is complicated when sensory
impulses are conducted to the higher or lower-level centers and excite several motor
impulses. If the arc, either in its sensory or motor limb or in the center, is interrupted, the
reflex is lost. Spinal reflexes are very important for survival and include the stretch reflex,
the Golgi tendon reflex, the crossed extensor reflex, and the withdrawal reflex3.
The stretch reflex, also called a myotatic reflex is a monosynaptic reflex that causes muscle
contraction in response to stretch within the muscle. These are the shortest latency reflexes
as they travel the shortest distance between the muscle and spinal cord and from the same
segment of the spinal cord that it entered to the muscle. The knee jerk reflex is an example
of a stretch reflex3.
Golgi Tendon reflex is a negative feedback mechanism that prevents the tendon from
breaking due to muscle force by causing muscle relaxation2. As tension builds in the
tendon, the Golgi tendon organ gets stimulated and propagates nerve impulses along the
sensory neurons into the spinal cord where it synapses with and activates an inhibitory
interneuron that releases the neurotransmitter glycine and inhibits the α motor neuron, a
neuron that innervates extrafusal muscle fibers of skeletal muscle and initiate contraction3.
Crossed extensor reflex is a contralateral stimulus that occurs on the opposite side of the
body from the stimulus. Upon receiving the stimulus, sensory nerve fibers cross to the
2

contralateral side of the spinal cord from the stimulated side of the body and synapse with
and inhibit the alpha motor neurons that innervate the muscles of the contralateral limb.
An example of this reflex action is when a person steps on a nail. The painful stimulus
propagates and causes the flexors of the ipsilateral leg (the one that experiences the
stimulus) to contract and extensors to relax. On the contralateral leg (the other leg that bears
the weight of the body) the flexors relax and the extensors contract to support the weight
of the body3.
Withdrawal reflex is a protective reflex that protects the body from damaging stimuli. It is
polysynaptic and an example is when a person withdraws his hand from a hot object even
without consciously wanting to do so. The sensory neurons get stimulated by the receptors
that receive heat and synapse with the interneurons that relay message to the motor neurons.
The motor neurons that innervate flexors allow them to withdraw from the stimulus3.
A reflex need to be sufficiently constant and noticeable to give importance to its alterations,
particularly in case of its absence, in normal subjects. Reflexes of the lower extremity are
more vital than those of the upper extremity and knee-jerk is the prominent among them.
Babinski reflex, ankle clonus, Achilles jerk, abdominal reflex, the cremasteric or inguinal
reflex, epigastric reflex, and planter reflex etc., are some of the other reflexes that are
important. Absent or diminished or exaggerated reflexes are indicative of diseases of the
central nervous system and muscles that are involved in that reflex4.
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Startle Reflex
The startle reflex response is induced by stimuli of adequate intensity reflecting the
activation of motor paths in the bulbopontine reticular formation of the brainstem. Within
a few milliseconds, facial and skeletal muscles are activated, leading the whole body to
flinch in rodents due to changes in the electrical activity. In rats, the startle response can
be observed within 5msec in the neck and 8msec in the hindleg. Neural pathways mediate
this acoustic startle response attributing to its very short latency. According to Davis et al.,
the acoustic startle response in the rat is mediated by three synapses-: 1) cochlear root
neurons; -, 2) neurons in the nucleus reticularis pontis caudalis and 3) motoneurons in the
facial motor nucleus or spinal cord5.

Figure 1
Difference Between Startle Response with and Without Prepulse Stimulus in Healthy
Individuals.
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Neural Pathway for Acoustic Startle Response
The neural pathway for Acoustic Startle Response begins in the cochlear nucleus
upon receiving the stimulus. This signal is transferred to the cells in the nucleus reticularis
pontis caudalis (PnC) located in the pons of the brainstem which then reaches the reticular
formation neurons that form circuits with the motor neurons of spinal cord or facial motor
neurons which control the muscle movements (fig.2)2,3. This causes the startle response6.
The startle response is adaptive in nature in terms of its plasticity in response that it can be
either be high or low depending on the intensity of the stimulus produced and the
circumstances. For instance, when the organism is in a state of emotional activation the
startle response is augmented because of a non-associative learning process called
sensitization or attenuated due to a process called habituation, which is because of repeated
presentations of stimulus. The other circumstance in which the startle reflex is decreased
is when presented with a low intensity stimulus before a startle stimulus, a process known
as prepulse inhibition1.

5

Figure 2
Trigeminal Pathway and Startle Response

Prepulse Inhibition, Sensorimotor Gating, and Schizophrenia
Prepulse inhibition plays a key role in filtering relevant and irrelevant sensory
information, alteration of which causes an overload of sensory information and can be used
as a measure of sensorimotor signaling which is impaired in patients with
Schizophrenia1fig.3). Several studies confirmed the presence of PPI disruption in
schizophrenia spectrum patients and in other disorders with disrupted gating mechanisms
which in healthy people involves an integrated symphonic array of time-coordinated events
across multiple sites that are brought about by a cascade of neurons in multiple loci. Thus,
PPI is considered as an operational measure of sensorimotor gating which gates out of
awareness the excess or insignificant stimuli, so that an individual can focus on the most
important aspects of the stimulus-loaded environment. We use the term sensorimotor
6

gating to describe the construct calculated by PPI because it is involved in the weak sensory
event or stimulus (the prepulse) inhibiting (or gating) the startle motor response to a
startling event or stimulus7.

Figure 3
Impaired Prepulse Inhibition in Schizophrenia Patients.

Animal studies suggest that PPI can be because of the descending forebrain circuitry of
cortico-striato-pallido-pontine (CSPP) interconnected substrates. The regulatory tone is
transmitted by the pedunculopontine nucleus from the forebrain via descending ventral
projections from ventral pallidum to the primary startle circuitry thus altering the inhibitory
effect of the prepulse stimulus on startle reflex. The psychopathological manifestations
observed in schizophrenia patients is because of this circuitry overlapping with the regions
7

associated with the disease symptoms. Sensorimotor signaling is further influenced by any
structural abnormalities in the brain regions related directly or indirectly to PPI regulation8.
Literature has constantly demonstrated the reduction in prepulse inhibition in patients with
schizophrenia compared to healthy subjects and has thus proposed PPI as a biomarker of
the disease1.
Schizophrenia
It is a serious psychotic illness characterized by an array of symptoms that can be
categorized into positive, negative and cognitive symptoms, which when left untreated can
be persistent and disabling. Positive symptoms include hallucinations, delusions and
thought disorder. Negative symptoms include avolition, anhedonia, flat affect and reduced
speaking. Cognitive symptoms of schizophrenia are subtle in some patients while in others
they are more prominent and include difficulty in decision making, paying attention, and
learning new things9. There are several theories as to what causes schizophrenia that center
on either an excess or a deficiency of neurotransmitters such as dopamine, serotonin, or
glutamate.
Dopamine Hypothesis of Schizophrenia
It is the widely accepted theory, and it involves four dopaminergic pathways
(fig.4). The low dopamine levels within the nigrostriatal pathway that extends from the
substantia nigra to caudate nucleus is responsible for motor symptoms. Excess dopamine
levels in the mesolimbic pathway that originates from the ventral tegmental area (VTA)
and ends in the limbic areas cause positive symptoms of schizophrenia. Negative symptoms
8

and cognitive deficits in schizophrenia are caused by dopamine levels in the mesocortical
pathway that extends from the VTA to the cortex. The decrease or blockade dopamine
levels in tuberoinfundibular pathway extending from the hypothalamus to the pituitary
gland results in elevated prolactin levels and causes galactorrhea, amenorrhea, and reduced
libido10.

Figure 4
Dopamine Pathways Involved in Schizophrenia
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Role of Dopamine Receptors. Heightened D2 receptor activation due to increased
subcortical release of dopamine is responsible for the positive symptoms and reduced D1
receptor activation in the prefrontal cortex for the negative symptoms of schizophrenia11.
Serotonin Hypothesis of Schizophrenia
This hypothesis was developed when a structural similarity between serotonin (5hydroxytryptamine; 5HT) and lysergic acid diethylamide (LSD), a hallucinogenic drug,
was established 40 years ago12. Drugs that blocked both dopamine and serotonin instead of
just dopamine were found to be more effective in alleviating both positive and negative
symptoms of schizophrenia11.
Glutamate Hypothesis of Schizophrenia
This theory is centered on the lack of glutamate, an excitatory neurotransmitter,
activity at the NMDA receptor. Increased co-agonists at NMDA receptor showed some
efficacy in clinical trials in schizophrenic subjects but not yet firmly established13.
Prepulse Inhibition and Other Psychiatric Disorders
Prepulse inhibition is deficient in patients with Huntington’s disease, obsessive
compulsive disorder, nocturnal enuresis, bipolar disorder, Asperger’s syndrome, fragile X
syndrome, 22q11 syndrome, Alzheimer’s disease, blepharospasm, and Tourette
syndrome14. Studies in OCD patients revealed dysfunctional PPI which was hypothesized
to be due to abnormalities in striatal regions and sensorimotor gating. In another study, it
was found that OCD patients with a history of a tic disorder were more likely to have PPI
deficiency15.
10

Huntington’s disease is a genetic neurodegenerative disorder that causes progressive
breakdown of nerve cells in the brain. Patients with HD have movement abnormalities,
cognitive impairments, and emotional disturbances16. Corpus striatum plays an important
role in inhibiting involuntary and intrusive movements. Degeneration of striatum in
Huntington’s disease causes a loss of motor inhibition which is manifested as abnormal
involuntary choreiform movements. Sensorimotor abnormalities or inhibition in such
patients can be measured using startle reflex17.
Bipolar disorder shows similar psychotic symptoms as schizophrenia such as
hallucinations and delusions. Deficits of PPI in bipolar disorder patients were like the
deficits in schizophrenia. Studies suggested that active manic symptoms and acute
psychosis might be responsible for PPI dysfunction in bipolar patients18.
Patients with major depressive disorder showed lower PPI values compared to the control
subjects in research studies but the impairment was not as profound as was observed in
patients with psychotic symptoms19.
Alzheimer’s disease is a progressive neurodegenerative disease that is characterized by
cognitive and memory deficits due to the structural and functional abnormalities including
neurofibrillary tangles, amyloid-β accumulation and neuron loss. Decreased prepulse
inhibition and increased latency to startle was observed in the transgenic mouse model
Tg4-4220.
Post-traumatic stress disorder is a condition that develops in people who have experienced
an injury or a traumatic event. In such patients, strong evidence from previous studies show
11

an increased baseline startle amplitude. PPI in PTSD patients isn’t quite conclusive yet due
to controversial results. Also, the causes of altered PPI values must be assessed with further
caution as baseline startle amplitude is elevated in the patients21.
Niemann Pick Disease Type C is a progressive genetic disorder characterized by the
lysosomal accumulation of lipids which causes neurodegeneration, dementia, ataxia, and
death. In some cases of adult-onset NPC, psychiatric disorders such as schizophrenia,
attention deficit hyperactivity disorder, and depression were pre-diagnosed suggesting
neural circuitry dysfunction precede the neurological symptoms. So, PPI can be used as a
diagnostic tool in NPC disease.
PPI in Previous Studies
PPI has been effectively studied in various neurological disorders, drug-challenge
studies and in studies of antipsychotic drug efficacy22. Studies were conducted to determine
the role of dopamine in prepulse inhibition of acoustic startle response and behavioral
variations among different genetic strains of mice23. Studies were also conducted to
determine a relationship between dopamine drugs and prepulse inhibition. Amphetamine,
an indirect dopamine agonist, was shown to decrease prepulse inhibition by increasing
dopamine overflow in nucleus accumbens markedly in one study while in the other
experiment, a combined treatment with subthreshold doses of SKF38393 and quinpirole,
selective dopamine D1 agonist and a selective dopamine D2 agonist, respectively, decrease
prepulse inhibition. Lastly, raclopride, a selective dopamine D2/D3 antagonist was shown
to increase prepulse inhibition24.

12

Parametric Effects on PPI
Prepulse
For the prepulse stimulus to inhibit startle response, it must precede the startle
stimulus by 30-500ms25. The stronger the prepulse stimuli the greater the Prepulse
Inhibition. In spite of this general rule, prepulse inhibition is not as straightforward as it
might appear at first. There is more than one factor on which the prepulse inhibition
depends, one among them being the background noise. The background noise is the
constant source of sound that is neither the prepulse nor the startle stimulus. Prepulse
stimulus arising from an uncontrolled ambient background does not elicit a reliable
relationship between prepulse and startle stimuli and sensorimotor gating as the exact same
brain processes are not involved in regulating prepulse inhibition arising from different
background noise levels25. The other factor on which the prepulse inhibition depends is the
prepulse duration. Bloch’s law stipulates that the stimulus salience reflects an interaction
of intensity and duration.
Prepulse-to-Pulse Intervals
Interstimulus interval (ISI), the onset of prepulse to the onset of pulse or startle
stimuli, for eliciting PPI normally ranges from 30 to 240 ms. ISI of 1000ms or more can
cause facilitation of the startle response magnitude in humans. Thus, in order to assess both
PPI and facilitation in a single experiment or a session, short and long ISIs can be used
respectively. In addition to the magnitude of the startle response, the pre-stimulus effects
on latency of the startle reflex response are quite important as the latency-to-startle onset
13

and latency-to-startle peak are measures of the rapidity with which the startling stimulus
evokes the startling response25.
Inter-Trial Intervals
Inter-trial intervals (ITI) lie within a range of 8-30 or more seconds with a range
centered around 15-20 seconds. Compared to fixed ITIs, variable ITIs causes less
habituation of startle reflex responses habituation and are thus more favorable for testing25.
Prepulse Type
Discrete white noise prepulses were observed to have maximal PPI effects in both
normal comparison subjects and schizophrenics in various studies25.
Aim
The main aim of the present study was to establish a working model that helps in
the discovery of effective novel dopamine drugs that can treat various psychoses. Tests
were conducted on two different strains of mice, all male, using haloperidol, a dopamine
receptor antagonist to demonstrate its effects on prepulse inhibition13.
Materials and Methods
Two different strains of mice, C57BL/6J and CD1, weighing 23–30 g at the start of
experiments were used. The C57BL/6J mice were obtained from Charles River
Laboratories (Wilmington, MA) and were housed in a room that was maintained at a
constant temperature at 21-23°C and humidity at 45-50% at a vivarium located in Cooper
Medical School of Rowan University at Camden. The vivarium has a barrier facility and
14

animals were kept under a 12h light/dark cycle (lights on at 0700 and off at 1900) in groups
of four per cage in polycarbonate cages with ad libitum food and water and enrichment
provided by paper Bio-Huts and/or nestlets. The mice were weighed and marked almost
every morning over the period of the research and monitored for general health and
behavioral parameters.
Animals
C57BL/6J
These are widely used in several different research studies because of their
availability and robustness. C57BL/6J are inbred mice strain developed by C. C. Little in
1921 which were handed over to Charles River in 1974 from NIH26. Also known as B6,
B6/J mice, C57BL/6J mice are used mainly in research areas like cardiovascular biology,
developmental biology, diabetes and obesity, immunology, genetics, and sensorimotor
research. Their preference for alcohol and morphine and sensitivity to noise and odors
make them the best fit for addiction and prepulse inhibition studies27. C57BL/6J’s are deep
brown to black in color with a tendency to bite. The dominant mice tend to remove hair
and whiskers of cage mates28.
CD1
These are the most popular strain of the outbred mice that are used in toxicology
and pharmacology research. The CD1 IGS mice are albino (have completely white hair)
with large genetic diversity similar to that found within and between human populations.
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They are docile and easy to handle compared to other types and display minimal evasive,
struggling, and aggressive behavior when caught and held29.
Drugs
Haloperidol was obtained from Sigma Aldrich, (St. Louis, MO, USA). It is a white
to faintly yellowish amorphous or micro-crystalline powder. It is poorly soluble in water
but freely soluble in chloroform, methanol, acetone, benzene, and dilute acids30.
Haloperidol is a first-generation butyrophenone antipsychotic drug active at postsynaptic
dopamine (D2, D3, and D4) receptors in the mesolimbic system of the brain. It is effective
in the management of the positive symptoms of Schizophrenia such as hallucinations,
delusions, hearing voices, aggression/hostility, disorganized speech, and psychomotor
agitation. Haloperidol along with other first-generation antipsychotics has side effects of
tardive dyskinesia, drug induced Parkinsonism, sedation, and weight gain31.
Three different doses, 0.1mg/kg, 0.3mg/kg, and 1mgkg, and a vehicle dose of haloperidol
were used in this study. The drug, 0.1N HCl and DMSO were vortexed until the drug
completely dissolved in the solution and finally saline was added to make up the volume.

16

Figure 5
Structure of Haloperidol

Apparatus
Prepulse Inhibition
A Med-associates apparatus was used. The mouse was held in a restraining tube
attached to a movement-sensitive plate and screwed onto a platform table in a sound
attenuating cubicle. To ensure proper functioning of the system, both the sound attenuating
chambers were calibrated using the “calibrate audio” utility and the ANL-929A-PC USB
microphone package17. Acoustic startle and prepulse stimuli were produced by a speaker
that fit snugly inside the chamber. The analog-to-digital converter converts the analog
voltage signal from the startle sensor to a digital unit.

17

Procedure
Two strains of mice, C57 and CD1, each with a different protocol were tested in
PPI. Two different software were used; Startle reflex, which is a manual setup software
and Startle pro, which is a highly automated software.
Startle Reflex Software
The pilot testing in C57 mice was divided into an initial acclimation period and
Block I startle only period with 6 trials, Block II prepulse plus startle period with 30 trials,
and Block III startle only period with 6 trials. Six different startle intensities between 95dBs
and 120dBs and five different prepulse intensities between 70-100 dB with rise/fall time
of 1 ms and 0 ms respectively and a 100 ms prepulse/startle delay were tested. In the next
stage, the same procedure with 0.1mg/kg, 0.3mg/kg, and 1mg/kg, doses of haloperidol or
vehicle (95% saline, 5% DMSO, 1N HCl) was tested. This protocol had two main
drawbacks. Firstly, prepulse noise levels itself caused startle in the animals. Secondly, the
drug solution caused ulcers at the site of injection and severe catalepsy which led to the
death of many mice. The testing was later carried out in cd1 mice with a modified protocol.
Initially, all the animals were acclimated to 70 dBs of white background noise for 15
minutes for three consecutive days. The next three days animals were subjected to varying
startle levels of 70 dB, 80 dB, 90 dB, and 100 dB. In the next stage, experiments were
conducted at four different startle intensities as in the previous step along with a prepulse
level of 70 dBs at three different frequencies of 4000 Hz, 12000 Hz, and 20000 Hz with
rise/fall time of 0ms and 3ms respectively and prepulse/startle delay of 100ms9. The testing
period was divided into 3 blocks with an initial 1-minute acclimation period at 70dBs white
18

noise. All the blocks had 18trials with both prepulse and startle stimuli. Prepulse
frequencies for block I, II, and III were set to 4000 Hz, 12,000 Hz, and 20,000 Hz,
respectively. In the next step, the same procedure was followed with 0.1 mg/kg, 0.3 mg/kg,
1 mg/kg doses of haloperidol or vehicle. Open field tests were conducted simultaneously
to study the effect of drug on locomotor properties of mice.
Startle PPI Software
8 Cd1 mice were used for testing in this procedure. Animals were initially
acclimated to the chambers for three days with constant white background noise at 60 dB
for 5 mins. The animals were then tested without any injections in the startle pro software
for 3 days. The test is highly automated, meaning all parameters are preset by the software.
The parameters include: 60 seconds acclimation, 10 msec prepulse duration, 3 msec
prepulse rise, 70 dB prepulse intensity at 3 different frequencies of 4, 12, 20 kHz, 100 msec
prepulse delay and, 10 msec startle duration, 0 msec rise, startle noise bursts of 70, 80, 90,
100 dBs, fixed sequence 3->8 seconds inter-trial-interval all summing up to 55 trials (24
with prepulse stimuli).
Statistical Analysis
Acoustic Startle responses evoked by 100-dB startle only (S2-only) intensities
without prepulses (S1s) establishes a baseline startle amplitude for each mouse. PPI for
each of the prepulse frequencies was calculated by dividing startle amplitudes with
prepulse amplitudes by baseline amplitude (S1+S2 trials / S2 only trials). Therefore, a
smaller ratio indicates stronger Prepulse inhibition.
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Results
8 male CD1 mice were tested using the Med-PC’s Startle PPI software. Animals
were acclimated to the chambers with 65dB white background noise the first three days
followed by the three-week testing period, first week without any injections, second week
with vehicle, 1 mg/kg, and 0.1 mg/kg doses of Haloperidol, and third week with the same
doses of 7-OH-DPAT.
Sixteen startle-only noise bursts, eight 70.04+100, eight 70.12+100, eight 70.20+100, five
70dB noise bursts, five 80dB noise bursts, and five 90dB noise bursts were produced. All
the data were trimmed prior to plotting on the graph to eliminate outliers.
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Figure 6
PPI Without Drug

Animals were tested at four different startle-only intensities, 70 dB, 80 dB, 90 dB, and 100
dB, and at three different prepulse + startle intensities (70 dB 4 kHz frequency, 70 dB 12
kHz frequency, and 70 dB 20 kHz frequency followed by 100dB startle noise. The data
shows an increase in startle response to the increase in startle noise. When preceded by a
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prepulse stimuli, startle response to startle stimuli reduced significantly. These results are
presented as means ± SEM.

Figure 7
Effect of Dopamine Drugs on Prepulse Inhibition

b
a
Note. Effect of two different doses of haloperidol(a) and 7-OH-DPAT(b) in startle response

at three different prepulse frequencies. No significant effects were produced by both the
drugs. Startle response increased with the increase in prepulse frequency in both the cases,
but the drugs have no consistent effect on the prepulse inhibition.
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Discussion
Prepulse inhibition is a measure of sensorimotor signaling that is impaired in
patients with Schizophrenia and thus can be used as a biomarker of the disease. When a
weaker pre-stimulus precedes the startle stimulus, PPI filters out the irrelevant stimulus
and decreases the sensory overload. Haloperidol, an antagonist at D2 receptor is used in
the treatment of positive symptoms of Schizophrenia. In the present study, Prepulse
inhibition of startle stimuli was measured at various sound intensities and frequencies.
Haloperidol and 7-OH-DPAT were injected to in the male CD1 mice to observe the effects
of Dopamine agonists and antagonists on prepulse inhibition. We expected to observe an
increase in prepulse inhibition with haloperidol and a decrease in prepulse inhibition with
7-OH-DPAT, but the data showed no such effects. However, in both the studies, a decrease
in startle response to startle stimuli when preceded by prepulse stimuli was observed
indicating that all the mice have intact prepulse inhibition and thereby the sensorimotor
gating.
There are limitations to this study. Firstly, the major limitation is the ineffectiveness of
haloperidol and 7-OH-DPAT on prepulse inhibition. In previous studies, haloperidol
prevented the disruption of PPI induced by dopamine agonists. Though 7-OH-DPAT
showed a significant disruption of PPI in other studies, in the present study it had no effect
on Prepulse inhibition. The effect of haloperidol on the disruption of 7-OH-DPAT (if any)
has not been assessed. Secondly, there are some sex mediated differenced in dopamine
receptor expression and signaling in humans and rodents. Since all the tests were conducted
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in male mice, there could be a significant difference in results if female were used for the
same studies32.
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Chapter 2
Niemann Pick Disease Type C
Introduction
Niemann Pick Disease Type C is a progressive genetic disorder characterized by
the lysosomal accumulation of lipids which causes neurodegeneration, dementia, ataxia,
and death. Cognitive impairments, severe motor deficits, and primary behavioral
disturbances are some of the other symptoms observed as the disease progresses. In some
cases of adult onset, psychiatric disorders such as schizophrenia, attention deficit
hyperactivity disorder, and depression were pre-diagnosed suggesting neural circuitry
disfunction precede the neurological symptoms.
Pathophysiology of NPC
NPC is caused by a mutation in NPC1 gene that encodes for a protein that is in the
limiting membrane of endosomes and lysosomes. The protein binds cholesterol to its Nterminal domain and mediates cholesterol trafficking. The mutations in NPC1 gene
includes small intragenic deletions/insertions, and missense, nonsense, and splice site
variants that cause the dysfunction of autophagic-lysosomal pathway in cells. This leads to
the formation of structural abnormalities and ectopic dendrites in mature neurons which
suggests that lysosomal dysfunction in NPC modifies neuronal structure and function.
During the developmental ages and after injury, neuronal autophagy and glial phagocytosis
are important for the structural and degenerative changes in dendrites and axons.
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In addition, autophagic-lysosomal activity inside the axons and in surrounding phagocytes
is important for the degeneration and removal of axon terminals during developmental
pruning but in case of NPC and other Lysosomal Storage Diseases (LSDS), lysosomal
dysfunction alters the process of synaptic pruning and removal of unwanted synaptic
structures during development. Purkinje cells are hypersensitive to the loss of NPC1
protein and degenerate earliest and to a greater severity than other neurons in the brain
which contribute to the development of early neurological symptoms such as clumsiness,
gait defects, and ataxia. Nevertheless, it is still unclear as to how the NPC1 deficiency
effects synaptic development at postnatal stages. Presumably, this susceptibility of
Purkinje cells to early neurodegeneration could possibly be because of intrinsic and/or
extrinsic pathological events during neurodevelopment caused by NPC1 deficiency. In
order to understand the underlying mechanisms involved in the early dysfunction and
degeneration of PCs, it Is important to detect the timeline of pathological changes in the
cerebellum caused by NPC1 deficiency. In a study with mice with complete NPC1 deletion,
microglial cells of neuroinflammatory phenotype were recognized as early as two weeks
of age and at 3 weeks genes associated with immune responses in the cerebellum showed
a change in their expression. A knockout mouse showed neurological symptoms at as early
as 4-5 weeks of age which made it difficult to find out if the neuroinflammation was caused
in response to the absence of NPC1 gene function in microglial cells or a result of PCs
degeneration or both.
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NPC and Neurological Disorders
Recent studies presented evidence to the contribution of microglial cells to the
developmental synaptic pruning defects in several neurological disorders like epilepsy,
schizophrenia, autism spectrum and fragile X syndrome. Interestingly, NPC in humans
cause neurological diseases that rapidly develops and progresses during childhood but
shows no apparent neurological symptoms during early infantile age. In addition to these
neurological diseases, some cases of juvenile and adult-onset NPC in humans were prediagnosed with psychiatric disorders like ADHD and schizophrenia due to cerebellar
dysfunction prior to the manifestation of the NPC neurological symptoms. This provides
the evidence that neural circuitry instabilities precede the loss of neurons in NPC and the
neurological symptoms which may alter psychomotor behaviors.
Current Research at Rowan
Microglial cells have the highest expression of NPC1 gene in brain which is why it
is important to understand how the NPC1 deficiency influences the proinflammatory
responses in the microglial cells and the disease progression. The late-onset NPC mouse
model at our laboratory showed neuroinflammatory responses in the synaptic region of the
cerebellum (molecular layer) of the brain such as microglial reactivity and monocyte
infiltration preceding the PCs degeneration. Moreover, PCs were degenerated by active
engulfing of calbindin and dendrites of PCs by IBA1 and microglia/macrophages which
suggest that preceding neuronal death, synaptic structures of PCs were targeted and
removed by phagocytes. Interestingly, by the end of postnatal development and before any
sign of PCs loss, the number of microglia at the synaptic region of the cerebellum at the
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molecular layer increased which lead to the conclusion that the abnormal development at
the molecular layer of the cerebellar synaptic structures along with microglial reactivity
due to NPC1 deficiency synergistically lead to synaptic defects that augment
neuroinflammatory responses in the cerebellum which precipitate the onset of PCs
degeneration.
Recent studies showed that cerebellar microglia have a gene expression that is different
from the microglia in other regions of the brain. Higher immune defense and
immunoregulatory genes were observed in healthy microglia obtained from cerebellum
than in the ones obtained from cortex or hippocampus. This shows that the microglia in
cerebellum are more immune-vigilant and deficiency of NPC1 in microglia is more
detrimental in cerebellar microglia than in the microglia from other parts of the brain.
Prepulse Inhibition in NPC
Previous studies showed a decreased prepulse inhibition in mice with NPC1nmf164
mutation compared to the wild type mice due to impaired sensorimotor gating.
Aim
The aim of this proposed research is to identify cellular and molecular pathways
involved in causing and progressing NPC in young patients from which effective
therapeutic interventions can be designed and tested to prevent or delay the onset of the
disease and prolong and improve the quality of life of young NPC patients. The first part
of the research plan was aimed at dissecting the effects of Npc1nmf164 mutation on the
microglial phenotype during cerebellar postnatal development. The second aim was to
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determine whether the Npc1nmf164 mutation affects developmental axon pruning in the
cerebellum. Finally, the third aim was to examine whether the mutation causes cerebellar
synaptic defects and psychomotor behavioral abnormalities before the degeneration of the
PCs.
The Npc1nmf164 mouse model is based on the C57BL/6J mouse strain with a point mutation
in NPC1. This mouse model has a single amino acid change from aspartate to glycine in
the cysteine-rich luminal loop of the NPC1 protein at position 1005 or bp 3163 and is very
similar to usually occurring human mutation. The factors that make Npc1nmf164 mouse
model a valuable model for understanding this disease and its progression are the location
of this mutation which is like that found in humans, late-onset and slower disease
progression. Breeding colonies were established for the knockout mice and tests were
conducted on knockout, heterozygous and wild type offspring on 21/22 day. Typically, in
humans, for a couple who are both carriers the chances of having an affected child is 25%,
a child who is a carrier is 50%, and a child who is unaffected is 25%. In NPC like recessive
genetic disorders, the risk is the same for both male and female offspring.
Animals
Heterozygous NPC1nmf164and wild-type C57BL/6J mice, weighing 23-30g at the
start of experiment were used. Upon arrival to the laboratory, the mice were given free
access to food and water in a room that was maintained at a constant temperature (21-23°C)
and humidity (45-50%) on a 12h light-dark cycle. Breeding colonies were thus established,
and the litter were genotyped on P18 by tail clipping and weaned on P20/21. Gestation
period for mice is typically 21 days so care was taken to wean the older pups before the
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arrival of the new litter. Behavioral studies were conducted from P21/22 depending on the
day of weaning.
Equipment
Open-Field Locomotor
This test was conducted in an apparatus obtained from med associates. It has four
chambers with cameras mounted on top of each chamber to monitor the movement of the
mice. All the chambers and the cameras were connected to the computer and run by Anymaze software. The field was divided into center region and outside regions, and the time
spent in the two regions was recorded.
Rotarod
This equipment has a horizontal rod that can be set to rotate at different speeds.
Mice were placed on the rod for 300seconds and the speed and time at which the mice
tripped off the rod was recorded.
Procedure
21/22-day old pups were tested in open field locomotor and rotarod equipment. The
pups were placed inside the boxes of locomotor equipment and tested for their locomotor
activity for 30 minutes to find out if there was a difference in movement among various
genotypes of mutant mice5. NPC1nmf164 mutant mice (knockout) have a delayed acquisition
of motor skills during development. All the animals in the colony were tested in rotarod
equipment for their motor skills. The animals were placed on a rod that rotates at a speed
of 4-40rpm and the time at which they fall onto the sensor plate before reaching the constant
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speed of 40rpm was noted down. At the end of 4 weeks, the animals were euthanized and
perfused.
Results
All the +/- (het), and +/+ (WT) were tested first on rotarod followed by open-field
locomotor for a span of 10 days to observe for any diminished motor activity by time.

Figure 8
Locomotor Activity of NPC Mice

Note. The Total Distance Travelled in Meters in the Open-Field Locomotor Chambers by
17 +/+, and 22 +/- C57 Mice. +/+ Mice Show Slightly but not Significantly More
Locomotor Movement Than +/- Mice.
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Figure 9
Rotarod Test in NPC Mice

Note. In Rotarod test, +/- and +/+ show an increase in motor activity day-1 through day-3
indicating no diminished motor activity. +/- shows a slightly better motor activity than +/+.

Discussion
NPC is a progressive genetic disorder that causes neurodegeneration leading to
severe motor and behavioral disturbances. It is caused by a mutation in NPC1 gene that
codes for a protein that is involved in cholesterol trafficking. NPC1nmf164 mutant mice
(knockout) have a delayed acquisition of motor skills during development. We
established breeding colonies to obtain knock-out mice and test them in rotarod, openfield locomotor and PPI. The breeding colonies produced abundant +/+ and +/- pups. No
knock-out mice were detected in the colony, hence tests were only conducted in the +/+
and +/- mice which produced no significant differences in their motor activity.
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The study was called to a halt due to a non-compliance issue that raised due to the
weaning of mice pups in the colonies prior to the protocol mentioned weaning date (P21).
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Chapter 3
Synergistic Antihyperalgesic and Antinociceptive Effects of Morphine and MP-III024, a Positive Allosteric Modulator at α2GABA and α3GABAA Receptors
Introduction
Opioids are drugs that relieve pain. Prescription opioids are used to treat moderate
to severe pain, but they are also associated with serious side effects like constipation,
euphoria, and respiratory depression. They are often misused for their euphoric effect.
Opioids interact with the opioid receptors in the central nervous system and the
gastrointestinal tract and cause pain relief and constipation, respectively33.
Classification
Based on Origin
Opioids are classified into either endogenous or exogenous opioids. Endogenous
opioids are the opioids that are produced by the body. There are three endogenous opioids:
•

Beta-endorphin

•

Enkephalin

•

Dynorphin

Exogenous opioids are not produced within the body. They are further classified into 3
types of based on their origin33.
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Table 133
Classification of Opioids Based on their Origin
Natural opioids

Morphine, Codeine, Thebaine, and Papaverine

Synthetic opioids

Methadone, Fentanyl, Pethidine, Alfentanil, Remifentanil,
and Tapentadol

Semi-synthetic opioids Heroin, Buprenorphine, Dihydromorphine, and oxycodone

Based on Opioid Receptors
There are three receptors at which opioids usually show their effects. They are mu
(MOP) receptors, delta receptors, and kappa receptors. Opioid receptors are G-proteincoupled receptors. Only after the discovery of these receptors was a series of endogenous
opioid ligands discovered in brain extracts. A fourth receptor with opioid-like receptor
activity called as the nociception receptor (NOP) was subsequently discovered.

35

Table 233
Clinical Effects of Opioid Receptors
MOP
Analgesia
Euphoria

DOP
Analgesia
Modulation of
MOP

KOP
Analgesia
Dysphoria

Respiratory
depression

Inhibit
dopamine
release

Diuresis

NOP
Analgesia
Sedation

Physical
dependence

Table 333
Opioid Receptors and their Respective Endogenous Ligands
Receptor
DOP
KOP
MOP

NOP

Endogenous ligand
[Met]-enkephalin
[Leu]-enkephalin
Dynorphin-A
Dynorphin-B
Β-Endorphin
Endomorphin-1
Endomorphin-2
Nociceptin/orphanin (N/OFQ)
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Table 433
Classification of Opioids Based on their Receptor Binding and Affinity
Full agonist
Morphine
Hydromorphone
Oxymorphone
Heroin
Codeine
Hydrocodone
Oxycodone
Meperidine
Methadone
Fentanyl

Partial agonist
Tramadol
Butorphanol
Pentazocine
Buprenorphine

Mixed agonist Antagonist
Nalbuphine
Naloxone
Butorphanol
Naltrexone
Buprenorphine
Pentazocine

Mechanism of Action
Opioid receptors are coupled to inhibitory G-protein coupled receptors Gαi or Gαo.
Opioids cause two types of inhibitions; Presynaptic or Postsynaptic.
Presynaptic inhibition: G protein is made of 3 subunits, α, β, and γ subunits. When an
opioid bind to the receptor, a number of structural and molecular changes occur at the G
protein and the α subunit dissociates from βγ subunit. βγ subunit interacts with the voltage
gated calcium channels on the presynaptic neuron that help in releasing the
neurotransmitter and prevents them from opening. This inhibits the action potential from
propagating from presynaptic neuron to postsynaptic neuron.
Postsynaptic inhibition: When opioids bind to the opioid receptors on the postsynaptic
neuron the α subunit dissociates from βγ subunit. βγ subunit interacts with the G protein
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coupled potassium channels, opens them and the potassium moves out of the cell. When a
neurotransmitter binds to the receptors on postsynaptic neuron and opens Na+ channels
(depolarization), the positive charge that is brought about by the Na+ ions is negated by the
K+ ions moving out thus causing hyperpolarization and inhibiting the action potential from
further propagation.
Gαi role: The α subunit of the G protein is involved in inhibiting the cAMP production.
Adenylyl cyclase is an enzyme, present in the plasma membrane, converts ATP to cAMP
which activates cAMP dependent protein kinases. Protein kinases are made of regulatory
subunit and catalytic subunit. cAMP binds to the regulatory subunit and gets dissociated
from the catalytic subunit. The catalytic subunit then phosphorylates the neuronal proteins
and channels which either activates or inhibits them. This in turn starts some signaling
pathways and stops some. Gαi/o interacts with the adenylyl cyclase and inhibits it converting
ATP to cAMP.
β-Arrestin signaling: β-Arrestin proteins play a significant role in signal transduction at G
protein-coupled receptors. β-Arrestins regulate especially Mu opioid receptor signaling by
receptor desensitization. Desensitization occurs by phosphorylating the GPCRs by
serine/threonine kinases called G protein coupled receptor kinases. The phosphorylated
GPCRs recruit β-Arrestin which blocks G-protein mediated signaling either by
desensitizing the receptors or internalizing the receptors34. Regulation of GPCRs by βArrestin is multifaceted and the other way in which they regulate is by activating the
mitogen-activated protein kinase (MAPK) downstream signaling cascade which inhibit G
protein signaling at these receptors for long periods35.
38

Analgesic Mechanism of Action
There are two pain pathways, ascending and descending. Ascending pathway sends
pain signals to the brain while descending pathway blocks the ascending pathway.
Ascending pathway: the pain stimulus gets propagated from the site of pain through the
primary sensory neuron which meets secondary sensory neuron in the spinal cord. The
secondary sensory neuron passes through the brain stem into the thalamus which processes
the sensory information and synapses with tertiary neurons that activate brain cortex that
is involved in giving meaning to the pain.
Descending pathway: The neurons in the descending pathway are normally inhibited by
the GABA neurotransmitter that are released from the inhibitory interneurons in the brain
stem. In response to pain certain neurons release endogenous opioids that bind to the
inhibitory interneurons in the descending pathway and prevents GABA neurotransmitter
release. Without GABA, the neurons in the descending pathway are no longer inhibited
and the endogenous opioid releasing interneurons in the spinal cord get activated and
inhibit the pain signal propagation between primary and secondary neurons of the
ascending pathway.
Exogenous opioids act the same way endogenous ligands do in activating the descending
and inactivating ascending pathway.
Opioid receptors are also present in the ventral tegmental area, and respiratory center which
upon binding with opioids causes addiction and respiratory depression, the two main side
effects associated with long-term opioid use.
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Addiction Mechanism
Mesolimbic pathway, also called the reward pathway connects ventral tegmental
area of the midbrain to the ventral striatum of the basal ganglia of the forebrain. Nucleus
accumbens and olfactory tubercle make up the ventral striatum. Nucleus accumbens plays
a pivotal role in the reward pathway. Dopaminergic neurons that extend from the ventral
tegmental area to the nucleus accumbens are regulated by GABAergic interneurons that
have opioid receptors. When opioids bind to the opioid receptors on the GABAergic
interneurons, GABA inhibition of dopamine release is stopped as a result of which
excessive dopamine is released which activates reward pathway inducing pleasure. After
repeated use of opioids, a direct association is developed between opioid and pleasure
which is called as drug liking.
Tolerance Mechanism
It is a condition when body requires more drug to produce same effects after
repeated use of the drug. Repeated Opioid use deplete the cAMP reserves in the body. To
achieve homeostasis and compensate for the anticipated loss of cAMP, neurons
preemptively produce more cAMP which makes the neurons hyperactive. Opioid intake
followed by this increase, decreases the cAMP as expected but to a level that is within the
normal range. For the opioids to produce effects similar to those in the early stages, the
dose needs to be increased. Other factors that contribute drug tolerance are receptor
phosphorylation that changes the receptor shape, receptor internalization, decrease in
number of receptors available for ligand binding, and receptor-effector uncoupling which
stops the downstream signaling pathways.
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Withdrawal Mechanism
Withdrawal symptoms are due to the increased cAMP levels in the body that
overfires the neurons. cAMP levels are spiked in order to compensate for the loss of it upon
opioid intake. In case of no drug present in the body, the cAMP that is produced by the
body preemptively (to achieve homeostasis like discussed previously) overfires the
neurons causing withdrawal symptoms. Ventral tegmental area, locus coeruleus, and
intestines are the most affected areas of the body.
Locus coeruleus is the site for norepinephrine synthesis in the brain. Locus coeruleus is
responsible for alertness or wakefulness in humans or causing psychological stress. It also
activates the sympathetic nervous system or fight or flight response of the body. Activated
sympathetic nervous system produces sweating, pupil dilation, increased heart and
breathing rates. Opioid use produces the opposite effects, while withdrawal symptoms
exaggerate the normal functions of locus coeruleus. When opioids bind to the opioid
receptors in locus coeruleus, common side effects of opioid use like drowsiness, sedation,
dry skin, pinpoint pupil, and decreased heart and breathing rate are observed. During
withdrawal, the over firing neurons cause jitteriness and insomnia, anxiety, excessive
sweating, wide dilated pupils, and rapid heart and breathing rate.
Opioid receptors on the neurons that innervate and control gut movement, when bound by
opioids cause constipation, a common side effect observed with opioid use. During
withdrawal, gut movement becomes rapid and expels feces even before enough water is
absorbed resulting in diarrhea.
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In the ventral tegmental area, the GABAergic interneurons that keep the dopaminergic
neurons in check become tolerant to opioids and regain their ability to inhibit dopaminergic
reward pathway even in the presence of opioids which causes the feeling of discomfort. To
avoid these consequences, patients continue to use opioids and fall into the category of
opioid use disorder.
Overdose Mechanism
Breathing is controlled by Pre-Botzinger complex in the brain stem. This complex
sends signals rhythmically to diaphragm and other respiratory muscles that enables
breathing. When breathing is stopped by the person for whatever reasons, the feedback
loop that has chemoreceptors detect increased carbon dioxide levels and decreased oxygen
levels in the blood and activates Pre-Botzinger complex that forces breathing. These
chemoreceptors and Pre-Botzinger neurons have opioid receptors and at high opioid doses,
they get shut down and the complex no longer forces the person to breath and is followed
by death.
Naloxone is an opioid receptor antagonist that binds and prevents morphine from binding
to the receptors thus preventing respiratory depression.
Uses of Opioids
Analgesia
Opioids are generally prescribed in the management of severe acute or chronic pain.
More than 100 million people in the United States suffer from acute and chronic pain and
around 6-8 million undergo long-term opioid treatment36. Opioid analgesics work
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effectively against both cancer and non-cancer pain. Intravenous opioid analgesics are used
to heal neuropathic pain like central pain, postherpetic neuralgia, and neuropathic pain
while oral opioid analgesics are effective against neuropathic, musculoskeletal, and other
non-cancer pain37. Morphine alone can manage severe cancer pain in almost 85% of the
patients. Combination therapy in the treatment of pain seems promising.
Edema
Morphine is a vasodilator and can be used in the treatment of pulmonary edema38.
Cardiogenic pulmonary edema is a condition in which the left ventricle cannot pump blood
efficiently out of the heart and builds up pressure. Morphine helps by acting as a vasodilator
and reducing hydrostatic pressure by lowering preload and afterload.
Diarrhea
Loperamide is an opioid agonist that acts like morphine and decreases the tone of
the longitudinal and circular smooth muscles thereby decreasing the peristaltic movement.
This increases the duration the material stays in the intestine and the water absorption from
the feces39. Opioids can also be used in the treatment of Irritable Bowel syndrome with
Diarrhea (IBS-D). Although there is no effective method available to treat IBS-D, opioids
can help in alleviating the symptoms. Eluxadoline is a Schedule IV drug approved by FDA
to manage IBS-D associated symptoms. The drug has a mixed pharmacology. It is an
agonist at MOR, and KOR, and antagonist at DOR. Since Eluxadoline acts locally by
targeting gut opioid receptors, CNS side effects are not common40.
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Cough Suppressant
Opioids act centrally by suppressing the cough center that is in the medulla
oblongata in the brain stem. Opioids are the only effective centrally acting anti-tussive
drugs that act through MOR and KOR agonism. Codeine is effective against acute and
chronic cough. Dextromethorphan is the most used anti-tussive that is as effective as
codeine. Hydrocodone is another opioid drug that is used as an anti-tussive, but it is only
available as a combination drug in the USA. The use of this drug with antihistamine drugs
often enhances the sedative effects of the drug due to which there is a limit to the maximum
dose a patient can take. Hydrocodone has fewer gastrointestinal side effects and is as
effective as codeine making it the drug of choice for cough41. Prescribing opioids as an
anti-tussive to patients below 18 years of age is not recommended by FDA42.
Anesthetic
Opioids are widely used as anesthetics in major surgeries, especially those
involving cardiovascular disease patients. Opioids do not cause cardiac depression making
them the drug of choice for inducing anesthesia in patients with cardiovascular diseases43.
Adverse Effects
The major adverse effects associated with opioids use is respiratory depression,
sedation, constipation, and bradycardia. Tolerance, hyperalgesia, dependence, and
immunologic effects, hormonal change, sleep disturbances, abuse, and addiction are other
side effects associated with opioid use44.
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Respiratory Depression
Opioids bind to the receptors located in the respiratory center or Pre-Botzinger
complex in the brain stem and induce respiratory depression. This opioid induced
respiratory depression initiates cardiorespiratory arrest with subsequent hypoxia and
hypercapnia resulting in fatalities. Mortality in opioid addicts that overdose on morphine
and heroin usually die of respiratory depression and respiratory failure.
Sedation
It is the second most observed adverse effect associated with opioid use. Opioids
are the primary choice of drugs used in the management of pain in hospitalized patients.
Sedation is a common adverse effect during first 24 hours of opioid therapy. To combat
this effect, opioids are often prescribed with other drugs like methylphenidate, which is a
first-line therapy for reducing sedation45. 10-15mg of methylphenidate has been observed
to reduce drowsiness significantly in cancer patients. Simultaneously, reducing opioid
doses without reducing analgesic effect may also be possible. Other drugs like
dextroamphetamine, donepezil, modafinil, and caffeine can be used to reduce opioid
induced sedation46.
Constipation
40-60% of the non-cancer patients receiving opioids experience opioid induced
constipation. Patients also develop other GI side effects like nausea, vomiting, bloating in
the stomach, abdominal pain, and straining. Stimulants like Senna or Bisacodyl are
administered with or without a stool softener and laxatives like magnesium citrate are used
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to prevent constipation. Lubiprostone increases fluid secretion in the GI tract by activating
type 2 chloride channel increasing the tone and peristalsis, accelerating the small bowel
and colonic transit times. Methylnaltrexone bromide, a peripherally acting opiate
antagonist is used in the treatment of opioid induced constipation. It does not cross the
Blood Brain Barrier to induce symptoms of opioid withdrawal making it the most superior
agent among all the available agents. Naloxegol, alvimopan, and naldemedine are approved
for the treatment of OIC in non-cancer pain patients47.
Cardiac Effects
Opioids cause bradycardia and vasodilation. Opioids when administered with other
medications like benzodiazepines, may decrease cardiac function. Methadone and
Buprenorphine are known prolong QTc, especially in patients at high risk for QTc
prolongation. Morphine, hydromorphone, hydrocodone, and meperidine decrease systemic
vascular resistance and blood pressure by releasing histamine48.
Tolerance
Opioid tolerance occurs when the same amount of drug shows reduced
responsiveness and is manifested as the need to use an increasing dose to achieve a desired
effect49. Increased doses of opioids given to counter tolerance can result increased opioid
associated adverse effects and opioid induced hyperalgesia. Factors that dictate the
development and extent of tolerance are the dose of drug and frequency of drug
administration.
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Hyperalgesia
Opioids induce hyperalgesia, a state of increased pain sensitivity following longterm use of high-dose opioids. It occurs when neoplastic modifications occur in both
peripheral and central nervous system. There are no well-established molecular
mechanisms as to how Opioid induced hyperalgesia occurs, but it could be due to the
molecular adaptations in MOR-expressing neurons that change the interaction between
cells and activate the independent oppositional system. In addition, opioid induced
apoptosis could also contribute to the development of hyperalgesia. This sensitization is
pain is a paradoxical response and the pain experienced in OIH can be very close to the
patient’s original pain50.
Immunologic Effect
Morphine has been observed to decrease the effectiveness of both natural and
acquired immunity in animal and human studies by interfering with the intracellular
pathways involved in immune regulation. Not all the opioids have same
immunosuppressive effects51. Morphine, codeine, methadone, fentanyl, sufentanil, and
remifentanil produce strong immunomodulating effect while oxycodone, tramadol,
buprenorphine, and hydromorphone produce weak immunomodulating effect. In selective
vulnerable populations like elderly or immunocompromised patients, opioid mediated
immune effects could be particularly risky. The least immunosuppressive opioid is
buprenorphine which is used as a first-line analgesic52.
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Hormonal Changes
Endocrinopathy (OE) is a term used to describe hormone problems. Opioids induce
endocrinopathy by affecting different hormones like testosterone, estrogen, luteinizing
hormone,

gonadotropin

releasing

hormone,

dehydroepiandrosterone,

and

adrenocorticotropin and corticotropin-releasing hormone, and cortisol. Opioids affect men
and women differently. In men, sexual disorders like erectile dysfunction, decreased libido,
depression and decreased energy levels are common side effects. Testosterone levels drop
significantly one to four hours after acute administration of opioids and takes around 24
hours to return to normal levels. Chronic administration of opioids results in tonic decrease
in both total and free testosterone levels53. In women, opioids cause depression,
dysmenorrhea, sexual dysfunction, and potentially reduced bone mineral density54.
Sleep Disturbances
Disorders of sleep-wake cycles, disorders of initiating and maintaining sleep.
Dysfunction associated with sleep stages and partial arousals are some of the sleep
disturbances that are associated with long-term opioid use such as in cancer patients55,56.
Studies showed that opioids can increase the number of sleep-wake transitions and reduce
the sleep time and efficacy57. Opioids alter the balance of neurotransmitters that regulate
sleep like serotonin, acetylcholine, noradrenaline, histamine, dopamine, GABA, melatonin
(sleep hormone), other pituitary hormones and affect sleep58.
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Opioid Addiction
Opioids have high abuse potential due as they induce euphoria and reduce negative
dysphoric moods59. Addiction is a chronic, relapsing disorder that is characterized by
strong desire to take the drugs even when medically unnecessary. Prescription opioids can
also cause addiction in people60.
The Opioid Epidemic
The Opioid epidemic is a major health concern occurring from the over-prescription
of opioids to relieve pain, increase in opioids use/abuse/overdose significantly impacting
patient health and economy. According to the center for disease control and prevention,
there are three different waves in the modern American opioid epidemic that raised the
mortality due to opioid overdose. The first wave was in 1990s, when opioids were
prescribed increasingly. The second wave was in 2010, when heroin caused large number
of overdose deaths. The third wave began in 2013 due to significant deaths due to synthetic
opioid overdosing, mainly those that were illicitly manufactured like fentanyl (IMF)61,62.
In 2016, 11.5 million Americans were misusing opioid prescriptions, more than 2.1 million
people had a diagnosable opioid use disorder and more than 42,000 died from opioid
overdosing. In 2017, US department of Health and Human Services declared a public
health emergency for this opioid crisis following 70,000 overdose deaths 63. Over the last
two decades, hundreds of thousands of lives have been lost and millions of people and their
families have been affected by opioid epidemic. Opioid misuse, abuse, and overdose have
been constantly surging in USA as well as in the whole world.
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Addiction Treatments
Opioid addiction has limited treatment options. Recovery requires Behavioral
therapy and Pharmacotherapy either individually or in combination along with counseling
and support64,65. Treatment is generally started with counseling, opioid replacement
therapy, and gradual discontinuation of the drug. Sudden discontinuation of the drug causes
severe withdrawal symptoms in which case drug detoxification is the only choice for the
physicians66.
New Analgesia and Strategy
NSAIDs and opioids are used in the treatment of pain. NSAIDs show weak
analgesic activity than opioids and act peripherally. Opioids act both centrally and
peripherally owing to their both central and peripheral side effects33. High abuse potential
of opioids raises the need for new treatment regimens and strategies in pain management.
Methods to Determine Analgesic Activity
To test analgesic agents, animals are subjected to nociceptive/painful stimuli prior
to administering an analgesic. The painful stimuli generates a response like jumping,
licking, shaking of the paws, skin twitch, tail flick, or flight which is indicative of painful
sensations. Popular methods for determining analgesic activity are
Writhing Test
Irritants like Phenylquinone or acetic acid are injected into the mice or rats in their
abdominal regions to induce pain and cause writhing. This is followed by the injection of
the synthesized analgesic compound which should decrease the frequency of writhing
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significantly67,68. This test is suitable to test for the analgesic profile of the peripherally
acting painkillers like chlorpromazine and meprobamate. The major drawback with this
test is that it is difficult to evaluate the analgesic duration as the frequency of writhing
decreases over time69,70.
Hot Plate Test
It is a thermal pain sensitivity test in which the rodents are placed on a hot surface
that is maintained at a specific temperature for a specific time frame and observed for
nocifensive activity like paw licking, fluttering, and jumping71. Upon injecting the animal
with analgesic drug, the latency to respond on hot plate increases indicating that the drug
is showing analgesic activity. Hot plate is a tricky test comparatively to other thermal
assays as rodents show very complex and subtle behavioral response72.
Von Frey Test
This is a mechanical pain sensitivity test. Animal is subjected to noxious stimulus
using a 50mm long filament of varying diameters. The animal is placed on an elevated
mesh screen and poked with filaments to different diameters to induce pain73. If the animal
withdraws the paw or starts licking or shaking the paws, it means the animal is feeling pain.
The exact force of the fiber is determined by its thickness. After injecting the analgesic
drug, the latency to respond to this painful stimulus increases indicating the analgesic
activity of the drug74.
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Tail Flick Test
This is one of the most common nociceptive assays. In this technique, heat is
applied to the animal’s tail and the pain sensitivity is determined by measuring the tail flick
latency75. If this latency is prolonged upon administration of the test drug, it indicates that
the drug has analgesic properties. The major drawback with this technique is that spinal
transection above the lumbar fails to block the tail flick response, thus it may not be
measuring the pain but the spinal nociceptive reflex76.
Formalin Test
This test is used to measure clinical pain due to injury. Dilute solution of formalin
is injected onto the planter surface of the rodent’s hind paw and is observed for rodent’s
stereotypical behavior such as flinching, licking, and biting of the affected hind paw which
are used as the measurements of inflammatory pain. These effects last for 15-60minutes77.
This method is preferred over other techniques because this model is useful to measure
both acute and tonic pain78 that affects inflammatory, neurogenic, and central mechanisms
of nociception79,80.

GABA Receptors
γ-aminobutyric acid is a neurotransmitter that has inhibitory activity in the CNS.
Inotropic GABAA receptors are one of the two major classes of GABA receptors that
include various αβγ2 isoforms assembled from varying α, β, and γ subunits with
differential signaling and expression patterns. Benzodiazepine-like drugs act as positive
allosteric modulators (PAMs) on α1GABAA, α2GABAA, α3GABAA, and α5GABAA
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receptors81. These receptors are distributed within the CNS with α2GABAA and
α3GABAA especially expressed in the Dorsal Horn Spinal pathway that is important to
nociceptive transmission82. Previous studies have demonstrated that intrathecally
administered benzodiazepines mediate antihyperalgesic effects via α2GABAA and
α3GABAA receptors at the level of the spinal cord83,84,85. Moreover, systemically
administered compounds with PAM activity at α2GABAA and α3GABAA receptors
showed reduced activity at supraspinally located α1GABAA receptors which mediate
side-effects of clinically used, commercially available benzodiazepines like
diazepam83,86,82,87,88.
μ-opioid receptors are co-expressed with α2GABAA and α3GABAA receptors in
nociceptive pain pathways which raises the possibility for interactive or combination
effects88. If supra-additive or synergistic effects are detected on endpoints related to pain
reduction, combination therapy may be useful to treat pain. A recent benzodiazepine-type
compound methyl 8-ethynyl-6- (pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a] [1,4]diazepine3-carboxylate (MP-III-024), with GABAA PAM effects was synthesized that displayed
functional selectivity for α2GABAA and α3GABAA receptors over other GABAA
receptors like α1GABAA and α5GABAA. This selectivity produced antihyperalgesic
effects with no off-target effects as observed with operant responding and locomotor
activity88. These data are along the same lines with other structurally related α2GABAA
and α3GABAA preferring ligands, HZ-16686 and KRM-II-8189. MP-III-024 is a close
analog of HZ-166 which showed non-sedating anxiolytic activity in rhesus monkey and
antinociceptive activity in rodents82,86. In addition, MP-III-024 showed a similar time
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course and duration of action compared to morphine, a prototypical μ-opioid receptor
agonist making it ideal for combination studies,88. In the present study, dose addition
analysis was used to assess α2GABAA / α3GABAA receptor-opioid interactions.

Materials and Methods

CD-1 mice 10 weeks of age were obtained from Charles River Laboratories.
Animals were housed in a vivarium that is maintained at a constant temperature and
humidity with constant access to air and water, under a 12h light/dark cycle (lights on at
7:00 AM). Mice were housed in groups of four in polycarbonate cages with ad libitum
food and water and enrichment provided by paper Bio-Huts and/or nestlets. No
experiments were conducted for 2 weeks upon their arrival to habituate them to the
colony room environment. Mice were handled for 2 days prior to the initiation of
experiments. Typical testing period was between 11:00 AM and 3:00 PM. Care of
animals was taken in accordance with the guidelines of the Institutional Animal Care and
Use Committee of Rowan University and all testing adhered to the “Guide for the Care
and Use of Laboratory Animals” (National Research Council, National Academy of
Sciences, Washington, D.C., USA, 2011).

Animals

CD-1 laboratory mice are used in biomedical and pharmaceutical research. They
are the progeny of nine Swiss mice, two male and seven female albino mice that were
imported to the USA by Dr. Clara Lynch of the Rockefeller Institute for Medical
Research, now named Rockefeller University in 1926.
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Experiments were started when the animals were 35 days old and were weighing
approximately 22-25 g. The animals were aggressive the first few days of handling and
gradually got accustomed to human handling.

Drugs

Methyl 8-ethynyl-6-(pyridin-2-yl)-4Hbenzo[f]imidazo[1,5-a][1,4]diazepine-3carboxylate (MP-III-024), the novel benzodiazepine analog was synthesized at the
Department of Chemistry and Biochemistry at the University of Wisconsin-Milwaukee.
Morphine was purchased from Sigma-Aldrich. 0.5% methyl cellulose dissolved in 0.9%
NaCl was used as a vehicle to suspend the drugs and was administered intraperitoneally
in a total volume of 10 ml/kg body weight.

Hot Plate Testing

A 25.3 × 25.3 cm measuring hot plate analgesia meter was used to assess
antinociception. The plate was maintained at 56 ± 0.1°C. The antinociceptive response
was measured by assessing the latency to lick or shuffle or flutter the hind paw(s) and/or
jump from the hot plate surface. To prevent tissue damage, a predetermined cutoff time
of 20 s was defined as a maximal response. The antinociceptive response was measured
at 30 and 15 min prior to the beginning of the drug administration and was used to yield a
baseline value.
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Apparatus

The hot plate analgesia meter (Columbus Instruments, OH) for small laboratory
animals were used for this analgesic test. (Figure 9) The hot plate could continuously
provide 55 °C temperature on an aluminum surface, with a digital built-in thermometer to
maintain surface temperature to 0.1 °C precision and a timer with a 0.1 sec precision. The
square shaped surface plate was enclosed by a clear acrylic cage to confine animals
during testing. Pushes on start/stop button related to the timer, which displayed the time
on the screen which was recorded manually90.
Procedure
The hot plate was maintained at 56 °C. Animals were placed on the surface of the
hot plate and observed for certain behavioral changes like paw licking, flutter, and
jumping, which indicates animal’s pain feeling. Latency time to respond to the stimuli
after placing the mice on the hot plate provided a threshold level. Two baseline studies
were conducted prior to injecting the animals with the drug. After weighing the animals,
testing drug was administered and animals were placed on hot plate in 15, 30, 45, 60
and/or 75/90 minutes time intervals to measure the latency time. The mouse was
immediately taken off the hot plate if any behavioral changes were observed and the time
was recorded. Animals were removed from the hot plate after 20 seconds even though no
considerable behavioral change was observed to avoid tissue damage. Animals that
showed a latency time more than 20 seconds were excluded from further investigation.
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Statistical Analysis
The anti-nociceptive effect for each dose was calculated as the % of the Maximal
Possible Effect (% MPE) using the following formula:
Latency time after drug administration − Mean latency time of baseline studies
%MPE = (
) X 100
{Maximal latency time (20) − Mean latency time of baseline studies}

Von Frey Test
A subcutaneous injection of 0.06 mg Zymosan A suspended in 20 µl 0.9% NaCl
was given into the plantar surface of the right hind paw to induce inflammation and study
antihyperalgesia and the e non-injected left hind paw was used as control. 24 hours after
the Zymosan A injection, mechanical sensitivity was measured by applying von Frey
filaments of increasing stiffness (5-26 g) to mid plantar surface of the hind paws until the
filament bends. Paw withdrawal response is indicative of positive response and the
mechanical threshold is defined as the minimum force necessary to elicit a positive
withdrawal response.
Apparatus
The apparatus consists of a mesh screen that is mounted on a stand at eye level.
Animals are placed on top the mesh and poked from below with von Frey filaments of
increasing stiffness of 0.008-300 g to determine the threshold that produces a hind paw
withdrawal response. The minimum gauge von Frey filament that causes a withdrawal
reflex is marked as the mechanical withdrawal threshold.
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Procedure
Each mouse was weighed, and baseline studies were conducted prior to injecting
drugs. Testing drug was injected, and the animals were placed on the wide gauge, wire
mesh surface in 15, 30, 45, 60, and/or 75/90 minutes time intervals and von Frey filaments
of increasing stiffness were applied until the filaments were seen to bend. If the same
filament made the mouse respond by flicking its paw away 3 times, the diameter of the
filament was recorded, and the process repeated with increasing gauges of von Frey
filaments that have different stiffness until stimulation forced a hind paw withdrawal.
Statistical Analysis
The mechanical threshold following drug administration was normalized to the
baseline measurement of the non-injected left hind paw and expressed as a percentage of
the maximal possible effect (%MPE) from the following formula:

%𝑀𝑃𝐸 = (

𝑝𝑜𝑠𝑡 𝑑𝑟𝑢𝑔 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔) − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑(𝑔)
) 𝑋 100
𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑙𝑒𝑓𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔) − 𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑟𝑖𝑔ℎ𝑡 𝑝𝑎𝑤 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑔)

Isobolographic and Dose-Addition Analysis
Graphical and statistical approaches were used to assess the interaction between
MP-III-024 and morphine. With the use of isobolograms, graphical approach made a
distinction between sub additive, additive or synergistic interactions. In the current study,
isobolograms were constructed by plotting and connecting the ED50 of MP-III-024 on
abscissa with the ED50 of morphine on ordinate to obtain an additivity line. The additivity
line had the loci of dose pairs that produce an ED50 equal to the ED50 of morphine or MP58

III-024 alone. Dose pairs that fell below the additivity line suggested ED50 was reached
with lesser quantities of the drugs which was suggestive of synergism and the experimental
points representing dose pairs that fell above the lone suggested subadditivity.
Drug interaction can be analyzed in different ways. Among them, a comparison of the ED50
values for each mixture with the predicted additive ED50 values is a good way to determine
the potency of the prospective combination drug. ED50 values for each mixture can be
represented by Zmix and predicted additive ED50 values can be represented by Zadd91. The
total drug dose of combined MP-III-024 and morphine that produces a 50% maximum
possible effect is called Zmix. If two drugs, e.g., morphine and MP-III024 added together
in a specific ratio have no sub- or supra-additive effects, the predicted additive response
can be measured by a predicted ED50 (Zadd). In this mechanical sensitivity assay, if both
drugs were effective equally, an equation Zadd = fA + (1 - f)B can be used to calculate
Zadd values individually. In that equation, A is the ED50 for MP-III-024 alone, B is the
ED50 for the morphine alone, and f is the fraction. For determining the proportion of MPIII-024 in each mixture equation fA/[fA + (1 - f)B] can be used. This study examined
effects produced by mixtures in which f = 0.25, 0.5, and 0.75. When f = 0.25, the mixture
contains a proportion of [A/(A + 3B)] MP-III-024 and a mixture ratio of [(A/B)/3] parts
MP-III-024 to one-part morphine; f = 0.50 leads to a proportion of [A/(A + B)] MP-III-024
in the mixture and a mixture ratio of (A/B) parts MP-III-024 to one-part morphine; and f =
0.75 leads to a proportion of [A/(A + B/3)] MP-III-024 in the mixture and a mixture ratio
of [(A/B) × 3] parts MP-III-024 to one-part morphine.
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Isobolograms were constructed to determine analgesic properties of morphine alone or in
combination with MP-III-024 in hot plate and von Fret test. In combination study, upon
plotting the ED50 on isobologram, three different cases were observed. Points representing
dose pairs can be on the additive line or lower-left side or upper-right side. If the points fall
on the additive line, no significant effects are possible of that combination. If the points
fall on the upper-right side, subadditive or counterproductive effects. If the points fall on
the lower-left hand side, supra-additive or synergistic effects are possible of that
combination. Upon testing with different ratios of the mixture in von Frey and hot plate, a
slight leftward shift of the ED50 values on isobologram were noticed.
Open-Field Locomotor Test
To test the effect of MP-III-024 on locomotion, an open field locomotor test was
conducted in drug naïve CD-1 mice. A cumulative dosing strategy was used in this
experiment. 3.2 mg/kg, 6.8 mg/kg. 8.0 mg/kg, and 14 mg/kg of morphine alone and MPIII-024 alone tests were conducted followed by 1:0.94 ratio of morphine to MP-III-024
drug mix.
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Results
Figure 10
Morphine and MP-III-024 in Von Frey and Hot Plate Technique

Note. Dose- effect curves of analgesic properties of morphine and MP-III-024 in von Frey
technique (left) and Hot plate technique(right). Morphine and MP-III-024 showed
effectiveness in the von Frey test. MP-III-024 induced antinociception comparable to
morphine. In the hot plate technique, Morphine showed a dose dependent effect, while MPIII-024 was with no effect.

Figure 10 demonstrates the dose response curves for morphine alone and MP-III-024 alone
in both the hot plate and von Frey procedures. In the von Frey test, the right hind paw that
was injected with Zymosan A showed reduced mechanical sensitivity relative to the noninjected left hind paw whose withdrawal threshold was unaffected (data not shown). In this
assay (right panel) each compound produced dose- and time-dependent increases in
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mechanical sensitivity as expressed as %MPE. A statistical test for parallelism revealed
that the morphine and MP-III-024 dose-effect curves were parallel (p < 0.05). These
relative potency values were used to determine relative proportions of the compounds used
in subsequent studies assessing MP-III-024/morphine mixtures. In the hot plate test,
Morphine produced a dose-dependent increase in the latency to respond to the thermal
stimulus while MP-III-024 was without effect in this assay. Thus, relative potencies
determined in the von Frey test were used to determine the relative proportions of the
compounds in each mixture90.
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Figure 11
Morphine Alone and Morphine+MP-III-024 Mixtures in Von Frey and Hot Plate
Technique

.

Note. Dose-effect curves of morphine alone and in combination with MP-III-024 in the
assay of mechanical hyperalgesia and in the assay of thermal nociception b. Abscissae,
cumulative dose of morphine in each mixture in mg/kg. Ordinate, antihyperalgesic (left) or
antinociceptive (right) effects of each drug expressed as percent maximum possible effect.
Each point shows the mean (± S.E.M.) from 8 mice90
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Figure 12
Isobolograms for MP-III- 024/Morphine Mixtures in the Assay of Mechanical and Thermal
Hyperalgesia

Note. Isobolograms for MP-III- 024/morphine mixtures in the assay of mechanical
hyperalgesia (a) and in the assay of thermal nociception (b). Abscissae, ED50 value for
morphine in mg/kg. Ordinate, ED50 value for MP-III- 024 in mg/kg. Each point shows the
mean (± S.E.M.) from 8 mice. *Significantly different from additivity90
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Figure 13
The Comparison of Locomotor Activity in Mice Injected with Morphine, MP-III-024, and
Morphine+MP-III-024.

Note. Figure 13 demonstrates the locomotor activity in mice when injected with morphine
alone, 0.94:1 ratio of MP-III-024 and morphine, and MP-III-024 alone. The curves indicate
that MP-III-024 can be as potent as morphine as an analgesic but with fewer side effects
than morphine.
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Discussion
Morphine and MP-III-024 showed a dose and time-dependent reduction in
mechanical sensitivity in von Frey procedure while in the hot plate procedure only
morphine was observed to be effective.
1:0.94 combination mixture of morphine and MP-III-024 demonstrates an interaction that
is synergistic in activity in both hot plate and von Frey procedures.
Variations in withdrawal response is an important tool used to assess changes in the tactile
sensitivity in mouse models of pain and inflammation. Nociceptive behaviors like paw
licking, flutter, and jumping and increased response latency following drug administration
was observed in hot plate technique and interpreted as an antinociceptive response. In von
Frey test, mechanical sensitivity induced by Zymosan A injection was reduced by each
compound and dose indicating the antinociceptive response. The two techniques showed
different effects for both the drugs but in combination, a synergistic effect raised the
possibility for a new combination of analgesics that could be used in lower doses and obtain
higher efficacy. Locomotor studies reveal the potential use of MP-III-024 as an analgesic
that has similar potency, time course and duration of action as morphine but with
significantly fewer adverse effects.
There are some limitations to this study. Firstly, all the tests were conducted in male mice.
Since there are sex-mediated differences in opioid signaling and expression, if the tests
were conducted in female mice the effect of combination study might have turned out to
be different. Secondly, all the animals were housed in light/dark cycle, but all the
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experiments were conducted during the day. The inactive part or the night part of the mouse
diurnal cycle may provide variable opioid receptor expression and opioid receptor
activation itself can change the circadian rhythms. If these tests were performed during the
dark cycle, there is a possibility that it could have yielded different results.
We aim to test GABAA PAMs such as HZ-166, or MP-III-080, and MP-III-024, in
combination with other opioids in the future.
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